Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This multi-center randomized Phase II study assigned HER2-negative early-stage breast cancer
patients to receive preoperative systemic chemotherapy in either a "genomic-guided" arm or a
"non-guided arm." The "genomic-guided" method (Arm 1) used genomic expression profiling to
assign the preoperative therapy (Doxorubicin/Cyclophosphamide (AC) versus
Docetaxel/Cyclophosphamide (TC), while Arm 2 used random assignment to these two therapies.